Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunitybio Inc (NQ: IBRX )

6.772 -0.268 (-3.80%)
Streaming Delayed Price Updated: 10:48 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunitybio Inc

< Previous 1 2 3 4 5 Next >
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
From ImmunityBio, Inc.
Via Business Wire
NASDAQ:IBRX Long Term Investor Alert: Investigation over Potential Wrongdoing at ImmunityBio, Inc.
San Diego, CA -- (SBWIRE) -- 11/03/2023 -- Certain directors of ImmunityBio, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END 
Via FinancialNewsMedia
5 Stocks with Unusually Large Short Interest
With the market soaring to new heights, fueled by the tech sector and hype surrounding AI, high short-interest stocks are again under the spotlight. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
From ImmunityBio
Via Business Wire
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
From ImmunityBio
Via Business Wire
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
From ImmunityBio
Via Business Wire
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
From ImmunityBio, Inc.
Via Business Wire
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities
From ImmunityBio, Inc.
Via Business Wire
IBRX DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important August 29 Deadline in Securities Class Action – IBRX
From The Rosen Law Firm, P.A.
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ImmunityBio, Inc. (IBRX)
From The Law Offices of Frank R. Cruz
Via Business Wire
NASDAQ:IBRX Investor Notice: Deadline on August 29, 2023 in Lawsuit Against ImmunityBio, Inc.
San Diego, CA -- (SBWIRE) -- 08/28/2023 -- The Shareholders Foundation announced that a deadline is coming up on August 29, 2023 in the lawsuit filed for certain investors of ImmunityBio, Inc.... 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
IBRX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses to Secure Counsel Before Important August 29 Deadline in Securities Class Action - IBRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
IMMUNITYBIO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
IBRX FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important August 29 Deadline in Securities Class Action - IBRX
WHY: NEW YORK, NY - (NewMediaWire) - August 22, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
IMMUNITYBIO, INC. (NASDAQ: IBRX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against ImmunityBio, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ImmunityBio, BioXcel, and Seagate and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A TOP RANKED FIRM, Encourages ImmunityBio, Inc. Investors With Losses to Secure Counsel Before Important August 29 Deadline in Securities Class Action - IBRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important August 29 Deadline in Securities Class Action - IBRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.